Proteoglycans are proteins that have glycosaminoglycans attached to them. The structure and function of proteoglycans varies greatly from one proteoglycan to another, but several of them are extracellular matrix components involved in cell adhesion. The biological and medical importance of cell adhesion has led us to charact3erize proteoglycans in this project. We have cloned the cDNAs of three different proteoglycan core proteins. These cDNAs will now be used in this component and in component IV to study the structure-function relationships in the proteoglycans. The complete proteoglycans, the core proteins and truncated forms of the core proteins will be expressed from cDNA constructs in mammalian cells and the functions of the products will be studied by various assays. Specifically, the function of the lectin-like and epidermal growth factor-like domains found in the core protein of the large fibroblast proteoglycan PG 350 will be studied by binding assays and by observing effects of the expression of these domains on cells expressing them. The latter type of experiment has recently given an important clue to the function of another proteoglycan, decorin. We have found that cells expressing decorin have a much flatter morphology and grow to a lower saturation density than cells containing the expression vector alone. These findings suggest that decorin may be at least partially responsible for the """"""""contact inhibition of growth"""""""" phenomenon. Moreover, since decorin is one of the extracellular matrix molecules the synthesis of which is increased by transforming growth factor beta, the inhibitory effect of this factor on the proliferation of some types of cells may be mediated by decorin. This possiblity and the mechanism of the decorin effect on cells will be explored in this component. Important information on the growth characteristics of cells and on proteoglycan functions should ensue.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA028896-13S1
Application #
3749797
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
009214214
City
La Jolla
State
CA
Country
United States
Zip Code
92037
McLean, G W; Brown, K; Arbuckle, M I et al. (2001) Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis. Cancer Res 61:8385-9
Assa-Munt, N; Jia, X; Laakkonen, P et al. (2001) Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 40:2373-8
Baneres, J L; Roquet, F; Martin, A et al. (2000) A minimized human integrin alpha(5)beta(1) that retains ligand recognition. J Biol Chem 275:5888-903
Ellerby, H M; Arap, W; Ellerby, L M et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-8
Wang, B; Yang, H; Liu, Y C et al. (1999) Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 38:12499-504
Miura, R; Aspberg, A; Ethell, I M et al. (1999) The proteoglycan lectin domain binds sulfated cell surface glycolipids and promotes cell adhesion. J Biol Chem 274:11431-8
Ruoslahti, E (1999) Fibronectin and its integrin receptors in cancer. Adv Cancer Res 76:1-20
Orend, G; Hunter, T; Ruoslahti, E (1998) Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 16:2575-83
Kodandapani, R; Veerapandian, L; Ni, C Z et al. (1998) Conformational change in an anti-integrin antibody: structure of OPG2 Fab bound to a beta 3 peptide. Biochem Biophys Res Commun 251:61-6
Arap, W; Pasqualini, R; Ruoslahti, E (1998) Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 10:560-5

Showing the most recent 10 out of 129 publications